SMO or PTCH-1 (Hedgehog)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

1 regimens on this page
1 variants on this page


All lines of therapy

Vismodegib monotherapy

Regimen

Study Years of enrollment Evidence
Hainsworth et al. 2018 (MyPathway) 2014-2016 Phase 2a

Eligibility criteria

  • SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations

Targeted therapy

Continued indefinitely

References

  1. MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains dosing details in manuscript PubMed NCT02091141